Locally advanced oral squamous cell carcinoma patients treated with photobiomodulation for prevention of oral mucositis: retrospective outcomes and safety analyses

Author(s):Show less -

Brandao, Thais Bianca ^{[1, 2]} ; Morais-Faria, Karina ^{[1, 2]} ; Prado Ribeiro, Ana Carolina ^{[1, 2, 3]} ; Rivera, Cesar ^[2] ; Salvajoli, Joao Victor ^[4] ; Lopes, Marcio Ajudarte ^[2] ; Epstein, Joel B. ^{[5, 6]} ; Arany, Praveen R. ^{[7, 8, 9, 10, 11, 12]} ; de Castro, Jr., Gilberto ^[13] ; Migliorati, Cesar Augusto ^[14] ; Santos-Silva, Alan Roger ^{[1, 2]}

Affiliation:Show less -

^[1] Univ Sao Paulo, Fac Med, ICESP, Dent Oncol Serv, Sao Paulo - Brazil

^[2] Univ Campinas UNICAMP, Piracicaba Dent Sch, Semiol Area, Oral Diag Dept, Piracicaba Dent Sch, Ave Limeira 901, BR-13414903 Sao Paulo - Brazil

^[3] Univ Brasil, Sao Paulo - Brazil

^[4] Univ Sao Paulo, Fac Med, ICESP, Radiotherapy Serv, Sao Paulo - Brazil

^[5] Cedars Sinai Hosp Syst, Samuel Oschin Comprehens Canc Inst, Los Angeles, CA - USA

^[6] City Hope Natl Med Ctr, Div Otolaryngol & Head & Neck Surg, Duarte, CA - USA

^[7] SUNY Buffalo, Sch Dent Med, Dept Oral Biol, Buffalo, NY - USA

^[8] SUNY Buffalo, Sch Dent Med, Dept Biomed Engn, Buffalo, NY - USA

^[9] SUNY Buffalo, Sch Engn, Dept Oral Biol, Buffalo, NY - USA

^[10] SUNY Buffalo, Sch Engn, Dept Biomed Engn, Buffalo, NY - USA

^[11] SUNY Buffalo, Sch Appl Sci, Dept Oral Biol, Buffalo, NY - USA

^[12] SUNY Buffalo, Sch Appl Sci, Dept Biomed Engn, Buffalo, NY - USA

^[13] Univ Sao Paulo, Fac Med, ICESP, Clin Oncol Serv, Sao Paulo - Brazil

^[14] Univ Florida, Coll Dent, Gainesville, FL - USA

• Document type: Journal article
• Source: SUPPORTIVE CARE IN CANCER; v. 26, n. 7, p. 2417-2423, JUL 2018.
• Web of Science Citations: 8

Abstract

The well-established clinical efficacy of photobiomodulation (PBM) therapy in management of oral mucositis (OM) is leading to increasing use in oncology care. This protection and enhanced repair of damage to mucosal tissue have led to the question of the potential effects of PBM therapy on pre-malignant and malignant cells. The purpose of this study was to examine the outcome of cancer therapy and incidence of tumor recurrence in locally advanced oral squamous cell carcinoma (OSCC) patients treated with PBM therapy for OM. A retrospective clinical analysis of 152 advanced OSCC patients treated with prophylactic PBM therapy for radiotherapy-induced OM from January 2009 to December 2014 was conducted. Of the 152 OSCC patients treated with PBM therapy in this study, 19 (12.5%) had stage III and 133 (87.5%) had stage IV tumors. Of these, 52 (34.2%) received initial treatment with surgery followed by adjuvant radiotherapy, 94 (61.8%) with exclusive chemoradiation, and 6 (4%) with induction chemotherapy followed by surgery and radiotherapy. After a mean follow-up of 40.84 (+/- 11.71) months, the overall survival and disease-free survival rates were 46.7 and 51.8%, respectively. Forty-five (29.6%) patients developed local-regional recurrence, 10 (6.57%) patients developed distant relapse, and 19 (12.5%) developed new (second) primary tumors. Clinicopathological features and survival outcomes in the PBM-treated patients were similar to previously published data for conventional treatments in patients with advanced OSCC. In this study, prophylactic use of PBM therapy did not impact treatment outcomes of the primary cancer, recurrence or new primary tumors, or survival in advanced OSCC patients. (AU)

• FAPESP's process: 12/06138-1 - A prospective study of radiation-induced trismus in patients with oral squamous cell carcinoma
• Grantee: Ana Carolina Prado Ribeiro e Silva
• Support Opportunities: Regular Research Grants
• FAPESP's process: 13/00429-7 - 2013 Annual Meeting (of The American Academy of Oral Medicine (AAOM)
• Grantee: Alan Roger dos Santos Silva
• Support Opportunities: Research Grants - Meeting - Abroad
• FAPESP's process: 13/18402-8 - Evaluation of the direct effects of radiation on the enamel, dentin and dental pulp of head and neck cancer patients
• Grantee: Alan Roger dos Santos Silva
• Support Opportunities: Regular Research Grants